Fulcrum Therapeutics announced it discontinued its sickle cell disease drug program due to FDA concerns about cancer risks linked to similar drugs. This led to a 51% drop in its stock price, prompting Kaplan Fox & Kilsheimer LLP to investigate potential securities violations. Investors who suffered losses are encouraged to contact the law firm. The investigation highlights regulatory challenges for treatments targeting the PRC2 complex.
Pineapple Financial, a mortgage lender listed on NYSE American, has tokenized over $1 billion in residential mortgage data on the Injective blockchain, marking a major step in blending traditional finance with blockchain technology. The project start...
Polymarket plans a $1 billion funding round valuing the prediction market platform at $21 billion, led by Donald Trump Jr.'s 1789 Capital. Cronos reversed its blockchain after a $75 million exploit in the Tectonic lending protocol, restoring the netw...
Investment-grade credit default swap (CDS) prices fell below 50 basis points, nearing lows not seen since February 2020, indicating improved credit market confidence. Meanwhile, the VIX volatility index dropped below 14 for the first time since Decem...
Hurco, a machine tool manufacturer, is showing signs of recovery after a tough industry downturn, with shares up over 30%. Recent results reveal strong year-over-year order growth but some sequential declines and regional differences, especially in E...
Hyperliquid's native token HYPE reached a new all-time high of $88, up over 51% in the past month, driven by strong trading volume and a $379 million buyback program. A large unidentified holder recently accumulated 2.9 million HYPE tokens, boosting ...
